X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (163) 163
Publication (7) 7
Book Review (2) 2
Patent (2) 2
Book / eBook (1) 1
Book Chapter (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (87) 87
life sciences & biomedicine (82) 82
humans (76) 76
female (54) 54
cardiovascular system & cardiology (52) 52
male (51) 51
cardiac & cardiovascular systems (50) 50
middle aged (49) 49
aged (46) 46
abridged index medicus (38) 38
myocardial infarction (31) 31
treatment outcome (30) 30
risk factors (28) 28
heart attacks (25) 25
acute coronary syndromes (21) 21
double-blind method (20) 20
ischemia (20) 20
mortality (20) 20
cardiovascular diseases (18) 18
coronary heart disease (18) 18
diabetes (16) 16
myocardial infarction - drug therapy (16) 16
myocardial infarction - mortality (16) 16
drug therapy (15) 15
secondary prevention (15) 15
cardiovascular disease (14) 14
kaplan-meier estimate (14) 14
stroke (14) 14
cardiovascular (13) 13
care and treatment (13) 13
patients (13) 13
follow-up studies (12) 12
general & internal medicine (12) 12
hemorrhage - chemically induced (12) 12
medicine, general & internal (12) 12
peripheral vascular disease (12) 12
time factors (12) 12
analysis (11) 11
cardiology (11) 11
diabetes mellitus (11) 11
dosage and administration (11) 11
drug therapy, combination (11) 11
percutaneous coronary intervention (11) 11
acute coronary syndrome - drug therapy (10) 10
aspirin (10) 10
cerebral infarction (10) 10
coronary artery disease (10) 10
heart attack (10) 10
platelet aggregation inhibitors - administration & dosage (10) 10
platelet aggregation inhibitors - therapeutic use (10) 10
prospective studies (10) 10
stroke - prevention & control (10) 10
acute coronary syndrome (9) 9
antiplatelet therapy (9) 9
confidence intervals (9) 9
heart diseases (9) 9
internal medicine (9) 9
original research (9) 9
percutaneous coronary intervention - methods (9) 9
platelet aggregation inhibitors - adverse effects (9) 9
zoology (9) 9
cardiac and cardiovascular systems (8) 8
cardiology and cardiovascular medicine (8) 8
clinical trials (8) 8
clopidogrel (8) 8
coronary angiography (8) 8
coronary vessels (8) 8
death (8) 8
kardiologi (8) 8
medical and health sciences (8) 8
medicin och hälsovetenskap (8) 8
myocardial infarction - diagnosis (8) 8
myocardial infarction - epidemiology (8) 8
primary percutaneous coronary intervention (8) 8
risk (8) 8
risk assessment (8) 8
ticagrelor (8) 8
ticlopidine - analogs & derivatives (8) 8
adult (7) 7
angina pectoris (7) 7
blood platelets (7) 7
cardiovascular diseases - mortality (7) 7
clinical medicine (7) 7
heart failure (7) 7
hospitalization (7) 7
klinisk medicin (7) 7
medical colleges (7) 7
medicine (7) 7
ornithology (7) 7
patient outcomes (7) 7
prognosis (7) 7
research (7) 7
usage (7) 7
acute coronary syndrome - mortality (6) 6
aspirin - administration & dosage (6) 6
atherosclerosis (6) 6
cardiovascular diseases - prevention & control (6) 6
cohort studies (6) 6
coronary artery bypass (6) 6
electrocardiography (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 10/2013, Volume 369, Issue 14, pp. 1317 - 1326
Saxagliptin, a new oral antihyperglycemic drug in the DPP-4 inhibitor class, had no effect on the risk of cardiovascular events in patients with type 2... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Adamantane - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Hypoglycemia - chemically induced | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Dipeptides - therapeutic use | Double-Blind Method | Pancreatitis - epidemiology | Dipeptides - adverse effects | Kaplan-Meier Estimate | Pancreatitis - chemically induced | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy | Heart diseases | Risk factors | Saxagliptin | Myocardial infarction | Cerebral infarction | Heart attacks | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Patients | Heart rate | Ischemia | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2012, Volume 366, Issue 15, pp. 1404 - 1413
Patients with atherosclerotic vascular disease were randomly assigned to receive the thrombin antagonist vorapaxar or placebo. Vorapaxar reduced the rate of... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Risk | Secondary Prevention | Pyridines - adverse effects | Cardiovascular Diseases - mortality | Female | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Pyridines - therapeutic use | Double-Blind Method | Hemorrhage - epidemiology | Receptor, PAR-1 - antagonists & inhibitors | Kaplan-Meier Estimate | Peripheral Arterial Disease - drug therapy | Stroke - drug therapy | Lactones - adverse effects | Lactones - therapeutic use | Retreatment | Myocardial Infarction - drug therapy | Brain Ischemia - drug therapy | Intracranial Hemorrhages - chemically induced | Intracranial Hemorrhages - epidemiology | Aged | Hemorrhage - chemically induced | Prevention | Drugs | Aggregation | Dose-response relationship (Biochemistry) | Atheroembolism | Blood platelets | Atherosclerosis | Product/Service Evaluations | Dosage and administration | Drug therapy | Myocardial infarction | Cerebral infarction | Stroke | Aspirin | Heart attacks | Proteinase-activated receptor 1 | Thrombin | Hemorrhage | Patients | Bleeding | Disease prevention | Ischemia | Arteriosclerosis | Death | Cardiovascular diseases | Health risk assessment | Index Medicus | Abridged Index Medicus | Computer Science | Medical Imaging
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2012, Volume 367, Issue 14, pp. 1297 - 1309
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2014, Volume 370, Issue 18, pp. 1702 - 1711
Darapladib, an oral inhibitor of lipoprotein-associated phospholipase A2, was compared with placebo in 15,828 patients with stable coronary heart disease.... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Stroke - prevention & control | Double-Blind Method | Follow-Up Studies | Oximes - adverse effects | Phospholipase A2 Inhibitors - administration & dosage | Humans | Middle Aged | Kaplan-Meier Estimate | Oximes - administration & dosage | Male | Coronary Artery Disease - drug therapy | Coronary Disease - mortality | Phospholipase A2 Inhibitors - adverse effects | Benzaldehydes - adverse effects | Benzaldehydes - administration & dosage | Coronary Artery Disease - complications | Treatment Failure | Coronary Disease - drug therapy | Female | Aged | Myocardial Infarction - prevention & control | Prevention | Care and treatment | Ischemia | Dosage and administration | Research | Coronary heart disease | Cardiovascular agents | Myocardial infarction | Cerebral infarction | Phospholipase A2 | Clinical trials | Myocardial ischemia | Cardiovascular disease | Angina | Preventive medicine | Coronary artery disease | Phospholipase | Arteriosclerosis | Death | Plasma levels | Drug therapy | Heart diseases | Plaques | Index Medicus | Abridged Index Medicus | Malalties cardiovasculars | Infart de miocardi | Malalties coronàries | Assaigs clínics de medicaments | Cardiovascular diseases | Drug testing | Coronary diseases
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2019, Volume 380, Issue 4, pp. 347 - 357
In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Abridged Index Medicus | Life Sciences | Food and Nutrition | Animal biology | Cellular Biology | Pharmaceutical sciences | Cardiovascular Diseases | drug therapy | Benzhydryl Compounds | complications | Sodium-Glucose Transporter 2 Inhibitors | Hospitalization | prevention & control | Klinisk medicin | Diabetes Mellitus | etiology | Clinical Medicine | epidemiology | statistics & numerical data | adverse effects | mortality | Type 2 | Heart Failure | therapeutic use | Glucosides
Journal Article
SA heart journal, ISSN 2071-4602, 09/2018, Volume 15, Issue 3, pp. 214 - 216
The South African Heart Association (SA Heart®) was established in 1999. Prior to 1999, 2 professional societies represented the interests of cardiologists and... 
South African Heart Association | history of the South African Cardiac Society | history of the South African Society of Cardiac Practitioners
Journal Article